NCT01641523

Brief Summary

Multicenter, prospective, comparative, observational study with regular follow-up visits. The project's aim is long-term follow-up of patients affected by large and complex craniolacuniae treated, in standard clinical practice, with CustomBone Service™ Cranial (porous bio-mimetic hydroxyapatite custom-made medical device for cranioplasty), autologous bone or polymethilmethacrylate customized prosthesis and to compare the clinical outcome and safety among the three treatments. Elegibility to each treatment will respect the standard clinical practice. Each investigator will respect his own hospital criteria for cranial reconstruction. Each centre's agreement to participate the study is totally voluntary. The study sample size has not been defined on statistical criteria: the study population was set at 100 consecutive patients treated with cranioplasty reconstruction with one of the three foreseen group. Each investigator will not be allowed to enrol more then 20 patients to avoid an enrolment imbalance between centres involved. Primary study end-points are: evaluation of adverse event incidence after surgical treatment. Secondary end-points are: quality of life improvement, evaluation of bone continuity restoration evaluated by CT scan analysis, neurological improvement.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
91

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2007

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2007

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2007

Completed
4.7 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2011

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

July 5, 2012

Completed
11 days until next milestone

First Posted

Study publicly available on registry

July 16, 2012

Completed
Last Updated

August 19, 2015

Status Verified

August 1, 2015

Enrollment Period

Same day

First QC Date

July 5, 2012

Last Update Submit

August 18, 2015

Conditions

Keywords

Cranioplasty prosthesisHydroxyapatitePolyMethylMethacrylateAutologous Bone

Outcome Measures

Primary Outcomes (1)

  • Safety

    incidence of adverse event (infection, reabsorption, mobilization, fractures, dislocation) after surgical treatment

    360 day after surgery

Secondary Outcomes (1)

  • Efficacy

    90, 180, 360, 720 days after the surgery

Study Arms (3)

Hydroxyapatite Cranioplasty

patient underwent to cranioplasty reconstruction with customized hydroxyapatite prosthesis

Device: CustomBone Service

polymethylmethacrylate

patient underwent to cranioplasty reconstruction with polymethylmethacrylate prosthesis

Device: CustomBone Service

autologous bone

patients underwent to cranioplasty reconstruction by autologous bone repositioning

Device: CustomBone Service

Interventions

customized hydroxyapatite cranial prosthesis

Also known as: polymethylmethacrylate cranioplasty, autologous bone opercula
Hydroxyapatite Cranioplastyautologous bonepolymethylmethacrylate

Eligibility Criteria

Age14 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

consecutive patients,in different italian centres, requiring cranioplasty

You may qualify if:

  • Patients which need cranial reconstruction,
  • Cranioplasty reconstruction by autologous bone, hidroxyapatite or polymethylmethacrylate,
  • Patients of both sex in age range between 14 and 75 years old,
  • Craniolacuniae size \> 25 cm2 ,
  • Patients affected by complex pathologies or fracture or infection of a previous implant.
  • Elegibility to CustomBone Service™ Cranial treatment will respect the product leaflet instructions.

You may not qualify if:

  • Patients affected by important emocoagulation pathologies,
  • Patients affected by mellitus diabetes,
  • Patients affected by autoimmune pathology,
  • Patients unable to intend,
  • Patients affected by immunodepression.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Franco Servadei, Prof. MD

    Maggiore Hospital Parma

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Franco Servadei, Prof. MD

Study Record Dates

First Submitted

July 5, 2012

First Posted

July 16, 2012

Study Start

January 1, 2007

Primary Completion

January 1, 2007

Study Completion

September 1, 2011

Last Updated

August 19, 2015

Record last verified: 2015-08